While reporting financial results for the third quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) raised its adjusted earnings guidance for the full-year 2025, while trimming annual revenue outlook.
For fiscal 2025, the company now projects adjusted earnings in a range of $2.55 to $2.65 per share on revenues between $16.8 billion and $17.0 billion. Previously, the company expected adjusted earnings in the range of $2.50 to $2.65 per share on revenues between $16.8 billion and $17.2 billion.
On average, analysts polled expect the company to report earnings of $2.56 per share on revenues of $16.88 billion for the year. Analysts' estimates typically exclude special items.
For the fourth quarter, the company reported net income attributable to Teva of $433 million or $0.37 per share, compared to a net loss of $437 million or $0.39 per share in the prior-year quarter.
Excluding items, adjusted net income for the quarter was $0.78 per share, compared to $0.69 per share in the year-ago quarter.
Net revenues for the quarter grew 3 percent to $4.48 billion from $4.33 billion in the same quarter last year. Revenues grew 1 percent in local currency terms.
The Street was looking for earnings of $0.67 per share on revenues of $4.33 billion for the quarter.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.